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Abstract
Purpose To investigate the impact of chemotherapy-induced
neurotoxicity on daily activities and quality of life (QoL) of
cancer patients.
Methods QoL of all patients visiting the oncological outpa-
tient ward of the Maxima Medical Centre in the Netherlands
from October 2006 until March 2007 treated with taxanes,
vinca-alkaloids and/or platinum compounds (n088) was com-
pared with the QoL of patients that did not receive these
treatments yet (n043). Patient-reported neuropathy symptoms
were evaluated with the newly developed Chemotherapy In-
duced Neurotoxicity Questionnaire (CINQ) and the Function-
al Assessment of Cancer Therapy/Gynaecologic Oncology
Group/Neurotoxicity (FACT/GOG-Ntx) questionnaire.
Results Patients treated with chemotherapy reported sig-
nificantly more complaints of neuropathy (p<0.001)
and more paresthesias and dysesthesias in the upper
(p<0.001; p<0.01) and lower extremities (p<0.001)
compared to those not treated with chemotherapy. They
additionally experienced problems with fine motor function
(e.g., getting (un)dressed, writing, and picking up small
objects). Moreover, cold-induced paresthesias were frequently
reported. Overall, patients indicated that their neuropathy had
a negative effect on QoL.
Conclusions The newly developed CINQ and the FACT/
GOG-Ntx results suggest a considerable negative impact of
patient-reported neuropathy symptoms on daily activities
and QoL in cancer patients treated with chemotherapy.
However, further validation of the CINQ is needed.
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Introduction
Chemotherapy, the major treatment modality in oncology, is
often accompanied by side effects, including peripheral
neuropathy. This may have a great impact on quality of life
(QoL) [1–5]. Peripheral neurotoxicity is caused by chemo-
therapeutic agents, like vinca-alkaloids, platinum com-
pounds, and taxanes [6]. The degree of neurotoxicity
depends on the type and combination of drugs used, the
duration of administration, and the cumulative dose applied
[7, 8]. Depending on the drug, sensory, painful neuropathies
(cisplatin, oxaliplatin and carboplatin) or combined senso-
motory neuropathies (vincristin and paclitaxel) may occur
[2, 8, 9]. In some cases, these symptoms first emerge or
worsen after cessation of chemotherapy, in particular in the
case of treatment with cisplatin [8, 10].
Attempts to evaluate the treatment of peripheral neuro-
toxicity have yielded promising, but variable results [6, 9–
14]. None of the known neuroprotective agents is currently
recommended as a standard treatment [6, 11, 15]. Currently,
peripheral neuropathy is treated symptomatically. Dose
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reduction or lowering dose intensities are typical ways to
prevent peripheral neuropathy, but this may also affect the
therapeutic potential.
Until now, there have been few systematic assessments of
the impact of peripheral neuropathy problems, which may
partly be explained by the lack of adequate measures. Spe-
cial neurotoxicity supplements have been added to QOL
measures, such as the FACT-taxane [1], the Functional
Assessment of Cancer Therapy/Gynaecologic Oncology
Group-Neurotoxicity (FACT/GOG-Ntx) [4], and the Che-
motherapy Induced Peripheral neuropathy (CHIP) [5, 7].
However, these measures fail to evaluate the effects of
neurotoxicity on daily functioning.
The aim of this study was to investigate the consequences
of patient-reported chemotherapy-induced neuropathy on
QoL with a newly developed Chemotherapy Induced Neu-
rotoxicity Questionnaire (CINQ). The FACT/GOG-Ntx was
used to validate the CINQ.
Patients and methods
Patients
All patients visiting the outpatient ward of the Department of
Oncology at the Maxima Medical Centre in the Netherlands,
between October 2006 and March 2007, who were treated
with taxanes, vinca-alkaloids and/or platinum compounds or
discontinued treatment less than a month ago were considered
eligible. Patients with other comorbid conditions potentially
causing CIN such as diabetes, thyroid disease or preexisting
neuropathy were excluded. Patients gave informed consent
before entering the study.
We compared patients prior to initiation of chemotherapy
(CT−; n043) with patients who had received at least three
cycles with taxanes, vinca-alkaloids or platinum compounds
(CT+; n088). In this group, data were collected within
1 month after cessation of therapy. The median number of
chemotherapy cycles per patient was 6, ranging from 3 to
14.
Measures
The newly developed CINQ was based on the questionnaire
by Leonard et al. [16] and interviews with seven patients
treated with vinca-alkaloids, platinum compounds or taxanes,
specifically asking about neurotoxicity symptoms, and their
impact on daily functioning. The preliminary CINQ was
evaluated by experts and was subsequently adjusted.
The final version consists of experienced symptoms: (A)
in arms, hands, fingers; (B) legs, feet, toes; (C) face and
mouth, (D) other symptoms, and how this affects QoL. Each
symptom question is followed by a question on the amount
of experienced bother and the influence on daily activities.
For example, “Do you experience cramps in your hands
(Yes/No)?” If yes; “How much did this bother you (range
0–5)?” and “Did this influence your daily activities (range
0–5)?” A high score indicates more severe patient-reported
neurotoxicity symptoms.
To assess the validity of the Dutch CINQ, the Dutch
version of the FACT/GOG questionnaire [2, 3] was used,
which can be used for patients with any form of malignancy.
This questionnaire contains 27 items, divided into four areas
of QoL: (1) physical well-being, (2) social/family well-
being, (3) emotional well-being and (4) functional well-
being. The validated Ntx extension of the FACT/GOG
questionnaire contains 11 questions which assess
chemotherapy-induced peripheral neuropathy [17]. A lower
score on the FACT/GOG indicates lower QoL. In addition, a
lower score on the NTX component means that patients
experience a greater impact of neuropathic symptoms in
their life.
Statistical analyses
We compared socio-demographic and clinical characteris-
tics of the CT+ and CT− group, using t-tests for continuous
variables and chi-square analyses for categorical variables
(Table 1). The Mann–Whitney test was used to evaluate the
differences in neuropathy between these groups (Table 2).
The association between the measures was computed with
the Pearson r correlation. Statistical test were two-sided and




Of the total group of 146 eligible patients, three did not
meet our inclusion criteria (brain metastases, a transverse
lesion, and no signed informed consent form). The socio-
demographic and clinical characteristics of the remaining
143 patients (88 CT+; 43 CT−) are compared in Table 1.
The groups did not differ significantly in terms of mean
age, sex and indication of treatment.
Impact of neurotoxicity on quality of life
CT+ patients reported significantly more complaints of neu-
ropathy compared to CT− patients (110 vs. 124; p<0.001)
as measured by the FACT/GOG. They also scored signifi-
cantly lower on the FACT/GOG-Ntx (33 vs. 41; p<0.001).
Finally, the CT+patients obtained significantly higher
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Table 1 Socio-demographic
and clinical characteristics of
patients treated with chemother-
apy (CT+) and a control
group (CT−)
ns Not significant
aCT−: control group of patients
before the start of their treatment
with chemotherapy
bCT+: patients with at least three
cycles of chemotherapy
cThe CT− patients’ column rep-
resents planned chemotherapy
regimens; the CT+ column rep-
resents patients that already un-
derwent at least three cycles of
chemotherapy
N (%)
Group CT− a (n043) Group CT+ b (n088) p Value
Socio-demographics
Age (mean (min/max) SD) 61 (36/79) 11.4 62 (36/81) 10.0 ns
Gender ns
Male 19 (44) 39 (44)
Female 24 (56) 49 (56)
Indication ns
Neo-adjuvant 1 (2) 4 (5)
Adjuvant 17 (40) 36 (41)
Curative 2 (5) 7 (8)
Palliative 23 (53) 41 (47)
Type of malignancy ns
Breast 7 (16) 13 (15)
Colon 16 (37) 29 (33)
Sigmoïd 3 (7) 9 (10)
Rectal 9 (21) 7 (8)
Gastric 0 6 (7)
Non Hodgkin lymphoma 1 (2) 8(9)
Prostate 0 7 (8)
Ovarian 2 (5) 5 (6)
Pseudo myxoma peritonei 1 (2) 0
Lung 0 (0) 1 (1)
Endometrial 0 (0) 2 (2)
Larynx 1 (2) 0
Multiple myeloma 1 (2) 0
Hodgkin lymphoma 1 (2) 0
Esophagus 0 1 (1)
Pancreatic 1 (2) 0
Chemotherapyc ns
Oxaliplatin 29 (67) 45 (51)
Paclitaxel 9 (21) 15 (17)
Docetaxel 0 12 (14)
Carboplatin 0 1 (1)
Cisplatin 2 (5) 8 (9)
Vincristin 2 (5) 7 (8)
Vinblastin 1 (2) 0
Table 2 Mean scores on
specific CINQ questions and
results of Mann–Whitney test
Paresthesia is a sensation of
tingling, pricking, or numbness
of a person’s skin
Dysesthesia is an unpleasant,
abnormal sense of touch
Mean score±SD (range)
Group CT− (n043) Group CT+ (n088) p Value
Paresthesia upper extremity 0.2±0.5 (0–2) 1.9±1.8 (0–5) <0.001
Dysesthesia upper extremity 0.2±0.7 (0–3) 0.8±1.3 (0–5) <0.01
Paresthesia lower extremity 0.3±0.8 (0–3) 1.5±1.7 (0–5) <0.001
Dysesthesia lower extremity 0.2±0.8 (0–4) 1.1±1.6 (0–5) <0.001
Paresthesia mouth 0.2±0.7 (0–4) 0.9±1.4 (0–5) <0.01
Paresthesia face 0.1±0.6 (0–4) 0.6±1.2 (0–5) <0.001
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scores on the CINQ (59 vs. 17; p<0.001) suggesting more
severe patient-reported neuropathy symptoms.
The CT+ group experienced significantly more pares-
thesias and dysesthesias in the upper (p<0.001; p<0.01)
and lower extremities (p<0.001) than CT− patients (Ta-
ble 2). In addition, the CINQ reveals that CT+ patients
had significantly more difficulty with fine motor func-
tion. They experienced more problems with buttoning up
a blouse (p<0.001), writing (p<0.003), and picking up
small objects (p<0.01). They further reported more cold-
induced pain when outside (p<0.001) and when taking
something out of the refrigerator (p<0.001), more prob-
lems with the consumption of cold foods (p<0.001) and
drinks (p<0.001) and more problems with controlling
their bladder function (p<0.05).
The CINQ further disclosed patients’ problems with
taking care of their environment due to neuropathies.
Patients experienced limitations in their activities due to
problems in hands, foot, or mouth (p<0.001) and they
mentioned difficulties with accepting the consequences
of neurotoxicity (p<0.001). Their neuropathies further
limited them with gardening (p<0.05) and sport activi-
ties (p<0.01). Overall, patients indicated that neuropathy
had a negative effect on QoL.
Criterion validity of the CINQ
Analyses showed a strong significant negative correlation
between the FACT/GOG and the CINQ (−0.73; p≤0.001)
which suggests that severe patient-reported neuropathy
symptoms were associated with a lower QoL. The Ntx and
the CINQ scores were also strongly correlated negatively
(−0.84; p≤0.001) which indicates that both questionnaires
assess a similar construct. However, the current findings are
preliminary and formal validation with clinical formal as-
sessment of neuropathy is still needed.
Discussion
Our findings suggest that neurotoxicity has a considerable
negative impact on daily activities and QoL in cancer
patients treated with chemotherapy. In particular, paresthe-
sias and dysesthesias in upper and lower extremities, prob-
lems with fine motor function, problems with controlling
their bladder function, and cold-induced paresthesias were
frequently reported. Most of these patients were treated with
oxaliplatin, which is known for its cold-induced paresthesias
[6, 8, 10, 15].
In previous studies, the influence of neurotoxicity on
QoL has been evaluated with the FACT-Taxane [1],
FACT/GOG-Ntx [2, 17] and the EORTC-QLQ-C30 [5, 7].
However, the specific effects of neurotoxicity on daily
activities and the inconveniences for the patient do not
become evident with these measures. Therefore, the CINQ
was developed and used in this study. The CINQ is unique
in revealing the problems in daily living caused by neuro-
toxicity. The strong association between the CINQ and
FACT/GOG can be considered as preliminary support for
its validity. With increasing neurotoxicity, a greater decrease
in QoL can be expected.
The degree of neurotoxicity as assessed in the present
study is hard to compare to other studies. There is currently
no consensus about the gradation of neurotoxicity. The
World Health Organization criteria [18], the Eastern Coop-
erative Oncology Group score [19], or the Ajani score [7]
are sometimes used, while in other studies nerve conduction
tests have been applied. In this study, no gradation has been
made.
Although our results showed a strong negative asso-
ciation between FACT/GOG and CINQ, and although
the FACT/GOG-Ntx subscale and CINQ scores were
strongly associated, the CINQ needs to be further eval-
uated, in particular its reliability and validity. Also, the
lack of an objective method of neurological assessment
as a reference is a limitation. In addition, the relatively
small number of patients did not allow us to investigate
the influence of differential exposure to the various
chemotherapeutic agents on patient-reported neuropathy
symptoms. Future studies should investigate this further.
Finally, the small number of included patients limits the
generalizability of the results.
Despite these limitations, the present study is the first
to provide support for the notion that neurotoxicity has
a great impact on daily functioning of cancer patients
and that these effects may require considerable adjust-
ments. It is important for health care professionals to
ask patients about problems related to neurotoxicity
since the impact on daily activities may be considerable.
Currently, hardly any treatment or preventive interven-
tions are available [6, 8, 9]. However, patients should
be adequately informed about possible side effects of
their treatment. The CINQ might be a useful and prom-
ising measure to evaluate patients’ suffering from neu-
ropathy symptoms. However, validation against clinical
formal assessment of neuropathy is still needed.
Acknowledgement The authors thank all patients for their participa-
tion in the study.
Conflict of interest None declared.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
880 Support Care Cancer (2012) 20:877–881
References
1. Markman M (1996) Chemotherapy-associated neurotoxicity: an
important side-effect impacting on quality, rather than quantity of
life. J Cancer Res Clin Oncol 122:511–512
2. Calhoun EA, Welshman EE, Chang CH, Lurain LR, Fishman DA,
Hunt TL, Cella D (2003) Psychometric evaluation of the Functional
Assessment of Cancer Therapy/Gynaecologic Oncologic Group-
Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving
systemic chemotherapy. Int J Gynecol Cancer 13:741–748
3. Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino
JP, Wieand S et al (2006) Validation of a self-reported neurotoxic-
ity scale in patients with operable colon cancer receiving oxalipla-
tin. J Support Oncol 4:W1–W8
4. Almadrones L, Deborah B, Guire M, Walczak J, Colleen M, Tian
C (2004) Psychometric evaluation of two scales assessing func-
tional status and peripheral neuropathy associated with chemother-
apy for ovarian cancer: a gynecologic oncology study group.
Oncol Nurs Forum 31:615–623
5. Postma TJ, Heimans JJ, Aaronson NK, Grant R, Huddart R, Maher
J, Hildehrand JG et al (1999) The impact of chemotherapy induced
peripheral neuropathy on quality of life. J Neurol Neurosurg Psy-
chiatry 67:838
6. Verstappen CP, Heimans JJ, Hoekman K (2003) Neurotoxic com-
plications of chemotherapy in patients with cancer: clinical signs
and optimal management. Drugs 63:1549–1563
7. Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced
peripheral neuropathy. Ann Oncol 11:509–513
8. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripher-
al neuropathy. J Neurol 249:9–17
9. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy.
Cancer Invest 21:439–451
10. Grothey A (2005) Clinical management of oxaliplatin-associated
neurotoxicity. Clin Colorect Cancer 5:38–46
11. Durand JP, Brezault C, Goldwasser F (2003) Protection against
oxaliplatin acute neurosensory toxicity by venlafaxine (effexor).
Anti-Cancer Drugs 14:423–425
12. Gamelin L, Bisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N,
Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neu-
rotoxicity by calcium and magnesium infusions: a retrospective
study of 161 patients receiving oxaliplatin combined with 5-
Fluoroucil and Leucovorin for advanced colorectal cancer. Clin
Cancer Res 10:4055–4061
13. Mielke S, Mross K, Gerds TA, Schmitdt A, Wasch R, Berger DP,
LangeWet al (2003) Comparative neurotoxicity of weekly non-break
paclitaxel infusions over 1 versus 3 h. Anti Cancer Drugs 14:785–792
14. Screnci D, Mc Keage MJ (1999) Platinum neurotoxicity: clinical
profiles, experimental models and neuroprotectieve approaches. J
Inorg Biochem 77:105–110
15. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical
aspects and molecular basis of oxaliplatin neurotoxicity: current
management and development of preventive measures. Seminars
Oncol 29:21–33
16. Leonard GD, Wright MA, Quinn MG (2005) Survey of
oxaliplatin-associated neurotoxicity using an interview-based
questionnaire in patients with metastatic colorectal cancer.
BMC Cancer 5:116–125
17. Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and
reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced
neurologic symptoms: a gynecologic oncology group study. Int J
Gynecol Cancer 17:387–393
18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Report-
ing results of cancer treatment. Cancer 47:207–214
19. Oken MM (1982) Toxicity and response criteria of the Eastern
Cooperative Oncology Group. Am J Clin Oncol 5:649–655
Support Care Cancer (2012) 20:877–881 881
